SPCC965.13 Antibody

What is SPCC965.13 Antibody and what are its key specifications?

SPCC965.13 Antibody is a polyclonal antibody raised in rabbits that specifically targets the SPCC965.13 protein from Schizosaccharomyces pombe (strain 972 / ATCC 24843, fission yeast) . The antibody is produced using a recombinant S. pombe SPCC965.13 protein as the immunogen and has been affinity-purified to enhance specificity . Its key specifications include:

The antibody is specifically designed for research applications in fission yeast studies and should not be used for diagnostic or therapeutic purposes .

How does SPCC965.13 Antibody differ from the related SPCC965.14c Antibody?

While both antibodies target proteins from Schizosaccharomyces pombe, they recognize different proteins with distinct functions:

• SPCC965.13 Antibody targets the SPCC965.13 protein (UniProt: O59833), with limited published functional information .

• SPCC965.14c Antibody recognizes the SPCC965.14c protein, which is described as a probable cytosine deaminase (EC 3.5.4.1) or cytosine aminohydrolase .

What validated applications exist for SPCC965.13 Antibody and how should they be optimized?

SPCC965.13 Antibody has been validated for two primary applications:

• ELISA (Enzyme-Linked Immunosorbent Assay): Useful for quantitative detection of the target protein in solution .

• Western Blot (WB): Allows for detection of the target protein in cell lysates separated by size .

For Western blot optimization, consider this methodological approach:

• Sample preparation: Prepare protein extracts from S. pombe using appropriate lysis buffers containing protease inhibitors.

• Protein quantification: Standardize loading using a reliable method (e.g., BCA assay).

• Electrophoresis: Use 10-12% SDS-PAGE gels based on the expected molecular weight of SPCC965.13.

• Transfer: Optimize transfer conditions (time, voltage) for your protein's molecular weight.

• Blocking: Use 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody: Start with a 1:1000 dilution in blocking buffer and incubate overnight at 4°C.

• Washing: Perform 4-5 washes with TBST, 5 minutes each.

• Secondary antibody: Use anti-rabbit IgG-HRP (1:5000) for 1 hour at room temperature.

• Detection: Use an appropriate chemiluminescent substrate.

For ELISA, perform antibody titration experiments to determine the optimal concentration that provides maximum specific signal with minimal background .

How can antibody characterization approaches enhance the reliability of experiments using SPCC965.13 Antibody?

Proper characterization of SPCC965.13 Antibody is critical for experimental reliability. The following characterization approaches should be implemented:

• Genetic validation: Use knockout or knockdown S. pombe strains lacking SPCC965.13 as negative controls to confirm antibody specificity .

• Orthogonal validation: Compare antibody-based detection results with antibody-independent methods such as mRNA quantification or mass spectrometry .

• Multiple antibody validation: When available, use independent antibodies targeting different epitopes of SPCC965.13 and compare results .

• Recombinant expression validation: Overexpress tagged SPCC965.13 and confirm detection with both the antibody and tag-specific antibodies .

• Immunocapture MS validation: Use immunoprecipitation followed by mass spectrometry to identify all captured proteins and confirm specificity .

These approaches align with the "five pillars" of antibody validation recommended by the International Working Group for Antibody Validation, which significantly enhances research reproducibility and reliability .

What are the optimal storage conditions for maintaining SPCC965.13 Antibody activity?

To maintain optimal activity of SPCC965.13 Antibody, follow these storage guidelines:

• Long-term storage: Store at -20°C or -80°C in the original buffer (50% Glycerol, 0.01M PBS, pH 7.4, 0.03% Proclin 300) .

• Avoid freeze-thaw cycles: Repeated freezing and thawing significantly degrades antibody performance .

• Aliquoting: Upon receipt, divide the antibody into small single-use aliquots to minimize freeze-thaw cycles.

• Short-term storage: For ongoing experiments, store working dilutions at 4°C for up to one week.

• Shipping and temporary transportation: Use ice packs or dry ice depending on transport duration.

Proper storage is critical as antibody degradation can lead to decreased sensitivity, increased background, and non-specific binding, all of which compromise experimental results .

What quality control measures should researchers implement when working with SPCC965.13 Antibody?

Implementing robust quality control measures is essential when working with specialized antibodies like SPCC965.13:

• Performance tracking: Maintain a laboratory record documenting antibody performance across experiments, noting lot numbers and storage conditions.

• Positive controls: Include the recombinant immunogen protein provided with the antibody as a positive control in each experiment .

• Pre-immune serum comparison: Compare results with the pre-immune serum provided in the antibody package to identify non-specific binding .

• Titration experiments: Periodically perform antibody titration to confirm optimal working concentrations remain unchanged.

• Batch consistency: When ordering new lots, run side-by-side comparisons with previous lots to assess consistency.

• Application-specific controls: For each experimental method, incorporate appropriate negative controls (e.g., secondary antibody only, isotype controls).

These quality control measures ensure experimental reliability and facilitate troubleshooting when unexpected results occur.

How can SPCC965.13 Antibody be incorporated into comprehensive S. pombe protein interaction studies?

For advanced protein interaction studies with SPCC965.13 Antibody, consider these methodological approaches:

• Co-immunoprecipitation (Co-IP): Use SPCC965.13 Antibody to pull down the target protein along with its interaction partners, followed by Western blot or mass spectrometry analysis to identify complexes.

• Proximity-dependent labeling: Express SPCC965.13 fused to BioID or APEX2, then use the antibody to confirm expression and compare with streptavidin pulldown results of proximity-labeled proteins.

• Crosslinking immunoprecipitation: Apply chemical crosslinking to stabilize transient protein interactions before immunoprecipitation with SPCC965.13 Antibody.

• Sequential immunoprecipitation: Perform tandem purification using SPCC965.13 Antibody and antibodies against suspected interaction partners to confirm direct interactions.

• Protein microarrays: Use purified SPCC965.13 protein to probe proteome-wide arrays, then validate identified interactions using the antibody in orthogonal assays.

These approaches provide complementary data that can effectively map the SPCC965.13 protein interactome in fission yeast, offering insights into its biological function.

What experimental design strategies are recommended for studying SPCC965.13 protein dynamics during the cell cycle?

To investigate SPCC965.13 protein dynamics during the cell cycle using the antibody:

• Synchronization experiments: Collect samples at different cell cycle stages using established synchronization methods (e.g., nitrogen starvation, hydroxyurea block) and analyze SPCC965.13 protein levels by Western blot.

• Time-course analysis: Following synchronization release, collect samples at regular intervals and quantify SPCC965.13 protein levels relative to cell cycle markers.

• Degradation kinetics: Employ cycloheximide chase experiments with SPCC965.13 Antibody detection to assess protein stability throughout the cell cycle.

• Post-translational modifications: Use phosphorylation-specific antibodies alongside SPCC965.13 Antibody to detect cell cycle-dependent modifications.

• Localization changes: If immunofluorescence is validated, track SPCC965.13 localization changes throughout the cell cycle, co-staining with organelle markers.

These experimental approaches should include appropriate controls such as asynchronous cultures and cell cycle marker proteins to ensure accurate interpretation of results.

What are common issues when using SPCC965.13 Antibody in Western blotting and how can they be resolved?

When using SPCC965.13 Antibody for Western blotting, researchers may encounter several technical challenges:

For all Western blot troubleshooting, include the recombinant immunogen as a positive control to benchmark expected results and antibody performance .

How can researchers validate SPCC965.13 Antibody for novel applications beyond manufacturer recommendations?

When extending SPCC965.13 Antibody use to applications beyond the manufacturer-validated ELISA and Western blot, follow this systematic validation approach:

• Preliminary specificity testing: First confirm antibody specificity in validated applications (Western blot/ELISA) using appropriate positive and negative controls.

• Knockout/knockdown validation: Generate or obtain SPCC965.13 knockout/knockdown S. pombe strains to serve as negative controls for the new application .

• Signal-to-noise optimization: Through systematic titration experiments, determine the optimal antibody concentration that maximizes specific signal while minimizing background.

• Protocol modifications: Adapt standard protocols by testing multiple fixation methods, incubation times, and detection systems.

• Orthogonal validation: Confirm findings using independent methods not relying on the antibody (e.g., mass spectrometry, RNA analysis) .

• Independent reproducibility: Have different laboratory members independently perform the new application to confirm reproducibility.

• Cross-validation: If available, test alternative antibodies against the same target in the new application.

This rigorous approach ensures that novel applications using SPCC965.13 Antibody will generate reliable and reproducible data suitable for publication.

How does using SPCC965.13 Antibody compare to alternative methods for studying S. pombe proteins?

When considering research approaches for studying SPCC965.13 in S. pombe, researchers should evaluate the relative advantages and limitations of antibody-based detection versus alternative methods:

This comparative analysis highlights the value of integrating multiple approaches, with antibody-based detection serving as a crucial tool for protein-level analysis while complementary methods address specific limitations .

What advantages do polyclonal antibodies like SPCC965.13 offer compared to monoclonal alternatives in research applications?

SPCC965.13 is a polyclonal antibody, which presents distinct advantages and limitations compared to monoclonal antibodies for research applications:

Advantages of polyclonal SPCC965.13 Antibody:

• Multiple epitope recognition: Recognizes multiple epitopes on the target protein, increasing detection sensitivity and tolerance to minor protein denaturation or modification .

• Batch production efficiency: Typically requires shorter production time and lower development costs than generating monoclonal antibodies.

• Robust signal amplification: Often provides stronger signals in applications like Western blot and immunohistochemistry due to multiple binding sites.

• Tolerance to fixation conditions: Generally more forgiving of various fixation and preparation methods.

Limitations compared to monoclonal alternatives:

• Batch-to-batch variation: Higher variability between production lots than monoclonal antibodies.

• Cross-reactivity potential: May have higher risk of non-specific binding to related proteins.

• Finite supply: Each production batch has finite volume and exact replication may be challenging.

• Standardization challenges: More difficult to standardize across laboratories and experiments.

For critical research requiring absolute epitope specificity and minimal batch variation, researchers might consider generating monoclonal antibodies against SPCC965.13, though this approach would involve significantly higher investment of time and resources.

How might SPCC965.13 Antibody be utilized in emerging research technologies and approaches?

SPCC965.13 Antibody can be leveraged in several cutting-edge research technologies:

• Super-resolution microscopy: If validated for immunofluorescence, the antibody could enable nanoscale visualization of SPCC965.13 protein localization and dynamics using techniques like STORM, PALM, or expansion microscopy.

• Single-cell proteomics: Combining the antibody with microfluidic-based single-cell isolation could reveal cell-to-cell variation in SPCC965.13 expression levels within yeast populations.

• CUT&Tag or CUT&RUN: If SPCC965.13 has DNA-binding properties, these techniques could map genomic binding sites with higher resolution than traditional ChIP-seq.

• Spatial transcriptomics integration: Correlating antibody-based protein detection with spatial transcriptomics data could reveal localized translation patterns and protein-mRNA relationships.

• Microfluidic antibody capture: Using microfluidic devices coated with the antibody could enable detection of secreted or released SPCC965.13 from live cells.

• Cryo-electron tomography labeling: Gold-conjugated antibody fragments could enable visualization of SPCC965.13 in near-native cellular contexts.

These applications would require thorough validation of the antibody in each specific context, particularly for techniques requiring secondary modifications or conjugations.

What methodological improvements might enhance the utility of SPCC965.13 Antibody in complex experimental systems?

Several methodological improvements could enhance SPCC965.13 Antibody utility:

• Site-specific conjugation: Direct conjugation to fluorophores, enzymes, or nanoparticles while preserving antigen-binding capacity would expand application range.

• Fragment development: Generation of Fab or scFv fragments would provide smaller probes with improved tissue penetration for imaging applications.

• Surface immobilization strategies: Optimized methods for antibody immobilization on biosensor surfaces would enable real-time interaction studies.

• Multiplexing capability: Development of SPCC965.13 Antibody compatible with multiplexed detection systems would allow simultaneous analysis of multiple proteins.

• Affinity maturation: In vitro evolution techniques could potentially enhance binding affinity and specificity.

• Cross-species validation: Systematic testing with related proteins from other yeast species would establish evolutionary conservation studies.

• Structural epitope mapping: Detailed characterization of epitope binding sites would improve understanding of detection capabilities and limitations.

These methodological improvements would significantly expand the research applications of SPCC965.13 Antibody beyond its current validated uses in ELISA and Western blot .